Senolytics: Difference between revisions

* 2019: Scientists at the Mayo Clinic report the first successful use of [[Senolytics|senolytics]], a new class of drug with potential anti-aging benefits, to remove [[Senescent Cells|senescent cells]] from human patients with a kidney disease.{{pmid|31542391}}

* 2021: Scientists report alternative approach to [[Senolytics|senolytics]] for removing [[Senescent Cells|senescent cells]]: invariant NKT (iNKT) cells.{{pmid|34617070}}

* 2022: Biomedical gerontologists demonstrate a mechanism of anti-aging senolytics, in particular of [[Dasatinib]] plus [[Quercetin]] (D+Q) – an increase of α-Klotho as shown in mice, human cells and in a human trial.{{pmid|35292270}}

* 2022: Scientists report that some apparently [[Senescent Cells|senescent cells]] – which are targeted by anti-aging [[Senolytics|senolytics]] – are required for regeneration, and suggest tailoring senolytics to precisely target harmful senescent cells while leaving the ones involved in regeneration intact.{{pmid|36227993}}

* 2023: First senolytics discovered using artificial intelligence: Teams from the University of Edinburgh and the Massachusetts Institute of Technology independently report the discovery of senolytics using artificial intelligence for screening large chemical libraries. The works reported compounds of comparable efficacy and increased potency than other known senolytics.{{pmid|37301862}}{{pmid|37142829}}